News

The FDA considers the recommendations of its advisory committees when making its determinations. If approved, ATryn will be the first recombinant human antithrombin available in the US, said

This Phase IIb trial is a randomized, open-label, multi-center, active-controlled, adaptive-design dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every four weeks plus daily

The proof-of-concept trial in hepatitis C virus (HCV)-infected patients is being conducted at multiple centers around the world. The trial design is a Phase I/II, double-blind, placebo-controlled, dose-escalation

Under the terms of the commercialization agreement, Illumina will exclusively market, sell, distribute and service Base technology products developed by Oxford Nanopore for DNA sequencing into the research

The Vu e-POD and Vu L-POD received clearance from the FDA to be marketed as a spinal intervertebral body fusion device (IBD). Prior to receiving the IBD status,

The Phase II trial involves treatment of patients with advanced, primary liver cancer refractory to standard therapies. Patients are randomized to receive treatment at one of two dose

The Phase II clinical trial, which began at the end of December 2008, is designed as a four-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability

The three new brands are Pacnex wash, a topical treatment for acne; Sumaxin cleansing pads, a topical treatment for acne, rosacea and seborrheic dermatitis; and Uramaxin nail gel,

The acquisition has been approved by Ablation Frontiers’s shareholders, and is subject to regulatory clearance. The transaction is expected to close in Medtronic’s fourth fiscal quarter, ending April